StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the stock.
Bio-Path Stock Performance
BPTH stock opened at $0.80 on Friday. The firm has a 50 day simple moving average of $0.96 and a 200 day simple moving average of $1.49. Bio-Path has a 52 week low of $0.61 and a 52 week high of $12.37.
Institutional Trading of Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- What Does a Stock Split Mean?
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Bank Stocks – Best Bank Stocks to Invest In
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- 3 Stocks to Consider Buying in October
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
